Clinical and Neurobiological Aspects of Narcolepsy

Overview

Journal Sleep Med

Specialties Neurology
Psychiatry

Date 2007 May 2

PMID 17470414

Citations 38

Authors

Seiji Nishino

Affiliations

Soon will be listed here.

Abstract

Narcolepsy is characterized by excessive daytime sleepiness (EDS), cataplexy and/or other dissociated manifestations of rapid eye movement (REM) sleep (hypnagogic hallucinations and sleep paralysis). Narcolepsy is currently treated with amphetamine-like central nervous system (CNS) stimulants (for EDS) and antidepressants (for cataplexy). Some other classes of compounds such as modafinil (a non-amphetamine wake-promoting compound for EDS) and gamma-hydroxybutyrate (GHB, a short-acting sedative for EDS/fragmented nighttime sleep and cataplexy) given at night are also employed. The major pathophysiology of human narcolepsy has been recently elucidated based on the discovery of narcolepsy genes in animals. Using forward (i.e., positional cloning in canine narcolepsy) and reverse (i.e., mouse gene knockout) genetics, the genes involved in the pathogenesis of narcolepsy (hypocretin/orexin ligand and its receptor) in animals have been identified. Hypocretins/orexins are novel hypothalamic neuropeptides also involved in various hypothalamic functions such as energy homeostasis and neuroendocrine functions. Mutations in hypocretin-related genes are rare in humans, but hypocretin-ligand deficiency is found in many narcolepsy-cataplexy cases. In this review, the clinical, pathophysiological and pharmacological aspects of narcolepsy are discussed.

Citing Articles

'It's like tumbleweeds everywhere': An Interpretative Phenomenological Analysis of the lived experience of being diagnosed with and living with narcolepsy.

Kilmartin B, Day W J Health Psychol. 2024; 29(12):1336-1349.

PMID: 38284414 PMC: 11459859. DOI: 10.1177/13591053231221373.

Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Excessive Daytime Sleepiness in Narcolepsy: A Network Meta-Analysis.

Zhan S, Ye H, Li N, Zhang Y, Cheng Y, Wang Y Nat Sci Sleep. 2023; 15:217-230.

PMID: 37082610 PMC: 10112483. DOI: 10.2147/NSS.S404113.

Hypocretin/orexin influences chronic sleep disruption injury in the hippocampus.

Nick H, Fenik P, Zhu Y, Veasey S Front Aging Neurosci. 2022; 14:1025402.

PMID: 36275002 PMC: 9582517. DOI: 10.3389/fnagi.2022.1025402.

Effects of the selective orexin-2 receptor antagonist JNJ-48816274 on sleep initiated in the circadian wake maintenance zone: a randomised trial.

Revell V, Monica C, Mendis J, Hassanin H, Halter R, Chaplan S Neuropsychopharmacology. 2021; 47(3):719-727.

PMID: 34628482 PMC: 8782905. DOI: 10.1038/s41386-021-01175-3.

Sleep dysregulation in binge eating disorder and "food addiction": the orexin (hypocretin) system as a potential neurobiological link.

Mehr J, Mitchison D, Bowrey H, James M Neuropsychopharmacology. 2021; 46(12):2051-2061.

PMID: 34145404 PMC: 8505614. DOI: 10.1038/s41386-021-01052-z.

References

Mignot E, Lin X, Arrigoni J, Macaubas C, Olive F, Hallmayer J . DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep. 1994; 17(8 Suppl):S60-7. DOI: 10.1093/sleep/17.suppl_8.s60. View

RICHARDSON G, Carskadon M, FLAGG W, van den Hoed J, Dement W, Mitler M . Excessive daytime sleepiness in man: multiple sleep latency measurement in narcoleptic and control subjects. Electroencephalogr Clin Neurophysiol. 1978; 45(5):621-7. PMC: 2391074. DOI: 10.1016/0013-4694(78)90162-1. View

Faraco J, Lin X, Li R, Hinton L, Lin L, Mignot E . Genetic studies in narcolepsy, a disorder affecting REM sleep. J Hered. 1999; 90(1):129-32. DOI: 10.1093/jhered/90.1.129. View

Dauvilliers Y, Neidhart E, Lecendreux M, Billiard M, Tafti M . MAO-A and COMT polymorphisms and gene effects in narcolepsy. Mol Psychiatry. 2001; 6(4):367-72. DOI: 10.1038/sj.mp.4000911. View

BOEHME R, Baker T, Mefford I, Barchas J, Dement W, Ciaranello R . Narcolepsy: cholinergic receptor changes in an animal model. Life Sci. 1984; 34(19):1825-8. DOI: 10.1016/0024-3205(84)90675-1. View

Black 3rd J, Silber M, Krahn L, Avula R, Walker D, Pankratz V . Studies of humoral immunity to preprohypocretin in human leukocyte antigen DQB1*0602-positive narcoleptic subjects with cataplexy. Biol Psychiatry. 2005; 58(6):504-9. DOI: 10.1016/j.biopsych.2005.04.026. View

KNECHT C, Oliver J, Redding R, Selcer R, Johnson G . Narcolepsy in a dog and a cat. J Am Vet Med Assoc. 1973; 162(12):1052-3. View

Martins P, DAlmeida V, Pedrazzoli M, Lin L, Mignot E, Tufik S . Increased hypocretin-1 (orexin-a) levels in cerebrospinal fluid of rats after short-term forced activity. Regul Pept. 2004; 117(3):155-8. DOI: 10.1016/j.regpep.2003.10.003. View

Kales A, Soldatos C, Bixler E, Caldwell A, Cadieux R, Verrechio J . Narcolepsy-cataplexy. II. Psychosocial consequences and associated psychopathology. Arch Neurol. 1982; 39(3):169-71. DOI: 10.1001/archneur.1982.00510150039009. View

10.

Bassetti C, Aldrich M . Idiopathic hypersomnia. A series of 42 patients. Brain. 1997; 120 ( Pt 8):1423-35. DOI: 10.1093/brain/120.8.1423. View

11.

Parkes J, Baraitser M, Marsden C, Asselman P . Natural history, symptoms and treatment of the narcoleptic syndrome. Acta Neurol Scand. 2009; 52(5):337-53. DOI: 10.1111/j.1600-0404.1975.tb05830.x. View

12.

Mitler M, Gujavarty K, Browman C . Maintenance of wakefulness test: a polysomnographic technique for evaluation treatment efficacy in patients with excessive somnolence. Electroencephalogr Clin Neurophysiol. 1982; 53(6):658-61. PMC: 2480525. DOI: 10.1016/0013-4694(82)90142-0. View

13.

Oka Y, Kanbayashi T, Mezaki T, Iseki K, Matsubayashi J, Murakami G . Low CSF hypocretin-1/orexin-A associated with hypersomnia secondary to hypothalamic lesion in a case of multiple sclerosis. J Neurol. 2004; 251(7):885-6. DOI: 10.1007/s00415-004-0442-z. View

14.

Nishino S . The hypocretin/orexin system in health and disease. Biol Psychiatry. 2003; 54(2):87-95. DOI: 10.1016/s0006-3223(03)00349-4. View

15.

Parkes J, Fenton G, Struthers G, Curzon G, Kantamaneni B, Buxton B . Narcolepsy and cataplexy. Clinical features, treatment and cerebrospinal fluid findings. Q J Med. 1974; 43(172):525-36. View

16.

Kaitin K, Kilduff T, Dement W . Evidence for excessive sleepiness in canine narcoleptics. Electroencephalogr Clin Neurophysiol. 1986; 64(5):447-54. DOI: 10.1016/0013-4694(86)90078-7. View

17.

Aston-Jones G, Bloom F . Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci. 1981; 1(8):876-86. PMC: 6564235. View

18.

Yoshikawa S, Suzuki S, Kanbayashi T, Nishino S, Tamai H . Hypersomnia and low cerebrospinal fluid hypocretin levels in acute disseminated encephalomyelitis. Pediatr Neurol. 2004; 31(5):367-70. DOI: 10.1016/j.pediatrneurol.2004.05.014. View

19.

Mignot E, Wang C, Rattazzi C, Gaiser C, Lovett M, Guilleminault C . Genetic linkage of autosomal recessive canine narcolepsy with a mu immunoglobulin heavy-chain switch-like segment. Proc Natl Acad Sci U S A. 1991; 88(8):3475-8. PMC: 51470. DOI: 10.1073/pnas.88.8.3475. View

20.

Bishop C, Rosenthal L, Helmus T, Roehrs T, Roth T . The frequency of multiple sleep onset REM periods among subjects with no excessive daytime sleepiness. Sleep. 1996; 19(9):727-30. DOI: 10.1093/sleep/19.9.727. View